Antibody therapy shows anti-tumour activity in advanced cancer
Drug Discovery World
MARCH 4, 2024
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of T immune cells by binding to a T cell receptor called CTLA-4.
Let's personalize your content